Clinical study of onestage lymphatics-venous anastomosis to prevent upper extremity lymphedema of breast cancer after radical resection

doi:10.3760/cma.j.issn.1673-422X.2016.01.001

Abstract

Abstract: Objective To investigate the value of onestage lymphaticsvenous anastomosis in radical mastectomy of breast cancer to prevent postmastectomy upper limb lymphedema. MethodsNinety patients requiring radical mastectomy of breast cancer in Tangshan Tumor Hospital Affiliated to North China University of Science and Technology from March 2010 to May 2013 were collected as the objects. They were divided into the control group (45 cases) and the treatment group (45 cases) using block randomized grouping (concealment of allocation). Both groups underwent radical mastectomy of breast cancer, and the treatment group was treated with onestage lymphaticsvenous anastomosis on the basis of radical mastectomy. The operation times, amount of bleeding, hospitalization times, postoperative complications and the numbers of axillary lymph node dissection of the patients in the two groups were compared, and the postoperative upper limb lymphedema incidence rates of the patients in the two groups were compared. ResultsThe operative times of the patients in the treatment group and the control group were (152.82±18.76)min and (78.92±10.33)min respectively, and amount of bleeding were (416.64±94.65)ml and (250.84±63.17)ml, with statistical significances (t=-20.39, P=0.00; t=-4.48, P=0.00). The average hospitalization times of the patients in the treatment group and the control group were (14.91±5.44)d and (13.45±2.36)d respectively, the numbers of axillary lymph node dissection were 14.63±3.37 and 14.37±3.18, the numbers of postoperative complications occurred were 9 cases (20.00%) and 5 cases (11.11%), with no statistical significances (t=-0.47, P=0.64; t=0.75, P=0.46; χ2=1.35, P=0.38). Compared with the control group, the treatment group has lower incidence of upper extremity lymphedema (13.95% vs. 40.91%) and lower swelling degree, with statistical significance (χ2=8.48, P=0.03). ConclusionOnestage lymphaticsvenous anastomosis in radical mastectomy of breast cancer can effectively transfer lymph diversion to the venous circulation and reduce the incidence of limb lymphedema, which has significant preventive effect.

Key words: Breast neoplasms, Lymphedema, Mastectomy, radical, Anastomosis, surgical

Shi Pengju, Zhao Gang, Cai Haifeng, Liu Huiren, Zhu Pengfei, Zhao Yanhui, Zhang Tieshan. Clinical study of onestage lymphatics-venous anastomosis to prevent upper extremity lymphedema of breast cancer after radical resection[J]. Journal of International Oncology, 2016, 43(1): 1-4.

References

［1］ Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients［J］. Ann Surg, 2007, 245(3): 452-461. DOI:10.1097/01.sla.0000245472.47748.ec. ［2］ Pusic AL, Cemal Y, Albornoz C, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patientreported outcome instruments and outcomes［J/OL］ . J Cancer Surviv, 2013, 7(1): 83-92. DOI:10.1007/s11764-012-0247-5. ［3］李树玲. 乳腺肿瘤学［M］ . 第2版. 北京: 科学技术文献出版社, 2007: 693. ［4］孟慧敏, 谷元廷, 李林. 乳腺癌前哨淋巴结活检替代腋淋巴结清除临床应用的观察［J］. 中华肿瘤防治杂志, 2012, 20(20): 1560-1562. ［5］张秀萍, 彭伟强, 李健, 等. 早期乳腺癌前哨淋巴结活检与腋窝局部放疗决策［J］. 重庆医学, 2006, 35(2): 117-118, 121.DOI:10.3969/j.issn.1671-8348.2006.02.011. ［6］ Auba C, Marre D, RodríguezLosada G, et al. Lymphaticovenular anastomoses for lymphedema treatment: 18 months postoperative outcomes［J］. Microsurgery, 2012, 32(4): 261-268. DOI:10.1002/micr.20980. ［7］侍朋举, 张文龙, 赵刚, 等. 改良静脉淋巴管吻合技术治疗乳腺癌术后上肢淋巴水肿［J］. 中国修复重建外科杂志, 2015， 29(3): 339-342. DOI:10.7507/1002-1892.20150072. ［8］ Suami H, Chang DW. Overview of surgical treatments for breast cancerrelated lymphedema［J］. Plast Reconstr Surg, 2010, 126(6): 1853-1863. DOI:10.1097/PRS.0b013e3181f44658. ［9］ Campisi C, Boccardo F. Microsurgical techniques for lymphedema treatment: derivative lymphaticvenous microsurgery［J］. World J Surg, 2004, 28(6): 609-613.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654.